Palo Alto, CA – According to filings with the U.S. Securities and Exchange Commission, MaveriX Oncology is raising $20,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Steven Everett played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MaveriX Oncology

MaveriX is a globally-orientated biotechnology company focused on the discovery, development, and commercialization of targeted small-molecule cancer chemo-immunotherapies.Our technology approach leverages unexploited insights into cancer and immune cell metabolism within the tumor microenvironment which are common to all cancers. Our novel platform is designed to selectively deliver the tumor cell killing benefits of chemotherapy while generating a robust immune response to attack a wide range of cancers.

To learn more about MaveriX Oncology, visit http://www.maverixoncology.com/

Contact:
Steven Everett, Chief Executive Officer
650-862-3872
https://www.linkedin.com/in/stevenaeverett/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved